Prevention of Experimental Autoimmune Uveoretinitis by Vasoactive IntestinalPeptide | Infectious Diseases | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Streilein  JW Immune privilege as a result of local tissue barriers and immunosuppressivemicroenvironments.  Curr Opin Immunol. 1993;5428PubMedGoogle ScholarCrossref
2.
Streilein  JWCousins  SW Aqueous humor factors and their effect on the immune response in theanterior chamber.  Curr Eye Res. 1990;9suppl175- 182PubMedGoogle ScholarCrossref
3.
Cousins  SWMcCabe  MMDanielpour  DStreilein  JW Identification of transforming growth factor-beta as an immunosuppressivefactor in aqueous humor.  Invest Ophthalmol Vis Sci. 1991;322201- 2211PubMedGoogle Scholar
4.
Taylor  AWStreilein  JWCousins  SW Identification of alpha-melanocyte stimulating hormone as a potentialimmunosuppressive factor in aqueous humor.  Curr Eye Res. 1992;111199- 1206PubMedGoogle ScholarCrossref
5.
Taylor  AWYee  DGStreilein  JW Suppression of nitric oxide generated by inflammatory microphage bycalcitonin gene–related peptide in aqueous humor.  Invest Ophthalmol Vis Sci. 1998;391372- 1378PubMedGoogle Scholar
6.
Taylor  AWStreilein  JWCousins  SW Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressiveactivity of normal aqueous humor.  J Immunol. 1994;1531080- 1086PubMedGoogle Scholar
7.
Pozo  DDelgado  MMartinez  JM  et al.  Immunobiology of vasoactive intestinal peptide (VIP) [published correctionappears in Immunol Today.2000;21:191]  Immunol Today. 2000;217- 11PubMedGoogle ScholarCrossref
8.
Delgado  MLaceta  JGomariz  RPGanea  D Vasoactive intestinal peptide and pituitary adenylate cyclase–activatingpolypeptide stimulate the induction of Th2 response by up-regulating B7.2expression.  J Immunol. 1999;1633629- 3635PubMedGoogle Scholar
9.
Avichezer  DSilver  PBChan  CCWiggert  BCaspi  RR Identification of a new epitope of human IRBP that induces autoimmuneuveoretinitis in mice of the H-2b haplotype.  Invest Ophthalmol Vis Sci. 2000;41127- 131PubMedGoogle Scholar
10.
Sun  BRizzo  LVSun  SH  et al.  Genetic susceptibility to experimental autoimmune uveitis involvesmore than a predisposition to generate a T helper-1–like or a T helper-2–likeresponse.  J Immunol. 1997;1591004- 1011PubMedGoogle Scholar
11.
Chan  CCCaspi  RRNi  M  et al.  Pathology of experimental autoimmune uveoretinitis in mice.  J Autoimmun. 1990;3247- 255PubMedGoogle ScholarCrossref
12.
Goetzl  EVoice  JKShen  S  et al.  Enhanced delayed-type hypersensitivity and diminished immediate-typehypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactiveintestinal peptide.  Proc Natl Acad Sci U S A. 2001;9813854- 13859PubMedGoogle ScholarCrossref
13.
Hara  YCaspi  RRWiggert  BDorf  MStreilein  JW Analysis of an in vitro–generated signal that induces systemicimmune deviation similar to that elicited by antigen injected into the anteriorchamber of the eye [published correction appears in J Immunol. 1992;149:4116]  J Immunol. 1992;1491531- 1538PubMedGoogle Scholar
14.
Zhang  MHung  LGery  I Vasoactive intestinal peptide (VIP) exacerbates endotoxin-induced uveitis(EIU) in mice.  Curr Eye Res. 2000;21913- 917PubMedGoogle ScholarCrossref
15.
Katayama  T The effect of vasoactive intestinal polypeptide (VIP) on ocular inflammationin rabbit ocular tissue [in Japanese].  Nippon Ganka Gakkai Zasshi. 1989;9316- 21PubMedGoogle Scholar
16.
Delgado  MAbad  CMartines  CLeceta  JGomariz  RP Vasoactive intestinal peptide prevents experimental arthritis by downregulatingboth autoimmune and inflammatory components of the disease.  Nat Med. 2001;7563- 568PubMedGoogle ScholarCrossref
Laboratory Sciences
August 2004

Prevention of Experimental Autoimmune Uveoretinitis by Vasoactive IntestinalPeptide

Author Affiliations

From the Department of Ophthalmology, Tokyo Medical University, Tokyo,Japan. The authors have no relevant financial interest in this article.

Arch Ophthalmol. 2004;122(8):1179-1184. doi:10.1001/archopht.122.8.1179
Abstract

Background  Vasoactive intestinal peptide (VIP), a neuropeptide that is known tobe present in lymphoid tissue microenvironments, shows prominent anti-inflammatoryactions.

Objective  To examine the potential effect of VIP on the development of experimentalautoimmune uveoretinitis (EAU).

Design  We immunized C57BL/6 mice with human interphotoreceptor retinoid-bindingprotein peptide 1-20 (h-IRBP peptide). Vasoactive intestinal peptide was administeredintraperitoneally on alternate days until day 21 after immunization (entiregroup). In some cases, VIP was injected at different time points after theinduction of immunity with h-IRBP peptide (efferent group). In each experiment,a control group of mice was injected with phosphate-buffered saline insteadof VIP. Development of EAU was evaluated by means of histological examinationon day 21 after immunization. Furthermore, we determined whether intravenousinjection of peritoneal exudate cells cultured with VIP overnight in vitroabrogated EAU. We analyzed delayed hypersensitivity for h-IRBP peptide andthe occurrence and severity of EAU using evaluation of histopathological sectionsfor inflammatory ocular disease.

Results  Treatment with VIP suppressed the expression of delayed hypersensitivityresponses to h-IRBP peptide significantly (positive control vs entire group, P = .02; positive control vs efferent group, P<.001). Mice treated with VIP (n = 10) showed a lower occurrence(40%) and decreased severity of EAU (entire group mean score, 0.3; medianscore, 0) compared with untreated mice (occurrence, 80%; mean score, 0.85;median score, 0.75), as assessed by histopathological analyses (P = .049). Suppressive effects of VIP on EAU were also observed, evenwhen VIP was administered on days 8 through 20 after immunization (efferentgroup [n = 9] occurrence, 11%; mean score, 0.1; median score, 0) (P = .003). Moreover, expression of EAU was significantly suppressedwhen the animals were pretreated with peritoneal exudate cells pulsed withh-IRBP in the presence of VIP (control mean score, 1.2; median score, 1.0;occurrence, 80% [n = 10]) compared with the VIP-treatment group (mean score,0.3; median score, 0; occurrence, 30% [n = 10]) (P =.004). In addition, VIP-treated peritoneal exudate cells generated regulatorT cells in the spleens of recipient mice that were able to interfere withthe development of EAU (control group mean score, 0.5; median score, 0.5;occurrence, 63% [n = 8]) compared with the VIP-treatment group (mean score,0.08; median score, 0; occurrence, 17% [n = 6]) (P =.08).

Conclusion  Treatment with VIP is a highly effective therapy to suppress EAU.

Clinical Relevance  As a result of its efficacy in preventing EAU, VIP might be consideredas a novel therapeutic modality for human uveitis.

×